Key clinical point: Of all the attributes a hypothetical preventive migraine medicine might have, survey respondents preferred a reduction in migraine days and an avoidance of weight gain.
Major finding: Patients with migraine were willing to pay $116 per month for an improvement from 10% to 50% in reduced headache days (95% confidence interval, $91-$141).
Study details: A web-based discrete-choice experiment survey of 300 respondents, all of whom self-reported having 6 or more migraine days per month.
Disclosures: Amgen and Novartis funded the study. The authors reported numerous conflicts of interest, including receiving grants, consulting fees, and royalties from pharmaceutical companies and organizations. During the study, three of the authors were employed at RTI Health Solutions, a non-for-profit organization that conducts research with pharmaceutical companies such as the study’s sponsor.
Mansfield C et al. Headache. 2019 May;59(5):715-26. doi: 10.1111/head.13498.